An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Genentech, Inc.
Study ID
NCT04250155
Phase
PHASE1
Status
Completed

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • XmAb24306 — DRUG
    Participants will receive intravenous (IV) XmAb24306.
  • Atezolizumab — DRUG
    Participants will receive IV XmAb24306 followed by IV atezolizumab
  • XmAb24306 — DRUG
    Participants will receive IV XmAb24306 followed by IV atezolizumab.

Study Details

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.

Key Dates

First listed
Jan 31, 2020
Start date
Mar 9, 2020
Status verified
Jul 2026
Primary completion
May 27, 2026
Completion
May 27, 2026

Study Design

Enrollment
195 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1a Dose Escalation
    Participants will receive XmAb24306 until study treatment discontinuation or study termination.
  • Experimental: Phase 1a Dose Expansion
    Participants will receive XmAb24306 until study treatment discontinuation or study termination.
  • Experimental: Phase 1b Dose Escalation
    Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
  • Experimental: Phase 1b Dose Expansion
    Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.

Primary Outcome Measure

Percentage of Participants with Adverse Events [ Time Frame: Up to approximately 4 years ]

Locations (6)

FacilityCityStateZIPSite coordinators
Honor Health Research InstituteScottsdaleArizona85258-
Stanford Health Centre - Palo AltoPalo AltoCalifornia94304-
University of California, San Francisco, Helen Diller Family Comprehensive Cancer CenterSan FranciscoCalifornia94158-2545-
Yale UniversityNew HavenConnecticut06520-
City of Hope Comprehensive Cancer CenterAnn ArborMichigan48109-
SCRI Oncology PartnersNashvilleTennessee37203-

Find similar trials in Scottsdale, AZ

By research site
Honor Health Research Institute· Scottsdale, AZStanford Health Centre - Palo Alto· Palo Alto, CAUniversity of California, San Francisco, Helen Diller Family Comprehensive Cancer Center· San Francisco, CAYale University· New Haven, CTCity of Hope Comprehensive Cancer Center· Ann Arbor, MISCRI Oncology Partners· Nashville, TN

Related Studies